Nivolumab plus chemotherapy vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 3-year follow-up from CheckMate 649

Video

Yelena Y. Janjigian, MD, reviews the 3-year follow-up data from the CheckMate 649 trial investigating nivolumab plus chemotherapy as a first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Related Videos
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Related Content